You are here
LEXEO Therapeutics LLC
UEI: GV7VALHZMNR7
# of Employees: 5
HUBZone Owned: Unavailable
Socially and Economically Disadvantaged: Unavailable
Woman Owned: Unavailable
Award Charts
Award Listing
-
CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration
Amount: $499,916.00Abstract. In partnership with the Crystal laboratory, Weill Cornell, LEXEO is developing an adeno-associ- ated virus (AAV)-based gene therapy to treat the central nervous system (CNS) manifestations o ...
STTRPhase I2020Department of Health and Human Services National Institutes of Health -
Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency
Amount: $252,042.00Abstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using in vivo gene therapy technologies to treat hereditary disorders of unmet medical need. LEXEO is developing a ...
STTRPhase I2020Department of Health and Human Services National Institutes of Health -
Oxidation-resistant Anti-protease Therapy
Amount: $1,499,103.00Abstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stress. LEX01, the 1st LEXEO product, is ...
STTRPhase II2019Department of Health and Human Services National Institutes of Health -
Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency
Amount: $224,970.00AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene ther ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Gene Therapy to Protect the Lung from Oxidant Stress
Amount: $224,593.00AbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Oxidation-resistant Anti-protease Therapy
Amount: $224,967.00AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnex ...
STTRPhase I2018Department of Health and Human Services National Institutes of Health
